What is Tirzepatide?
Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.
Video overview · 3:05
Tirzepatide: What the Trials Actually Show (Mounjaro and Zepbound Explained)
How it acts on two gut-hormone targets, what the SURMOUNT and SURPASS trials found (including a head-to-head trial against semaglutide), the side effects and label warnings, the outcome trials still under way, and its FDA approvals.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
Tirzepatide is a prescription medicine, sold as Mounjaro for type 2 diabetes and as Zepbound for weight management and sleep apnea. It acts on two gut hormone targets at once, and it has been tested in large trials with thousands of people. Here is what those trials actually show.
Tirzepatide is a single molecule that switches on receptors for two gut hormones, GIP and GLP-1. GLP-1 helps regulate appetite, and animal studies suggest GIP adds to that effect. People eat fewer calories, the body releases more insulin when blood sugar is high, and the stomach empties more slowly. How much the GIP part adds in people is less clear.
In SURMOUNT-1, about twenty-five hundred adults with obesity but no diabetes lost about fifteen to twenty-one percent of their weight on average over seventy-two weeks, versus about three percent on placebo. In SURMOUNT-5, a head-to-head trial, people lost about twenty percent on tirzepatide and fourteen percent on semaglutide. In sleep apnea, breathing interruptions fell by about twenty-five to twenty-nine an hour, versus about five on placebo.
The most common side effects are digestive: nausea, diarrhea, vomiting and constipation, mostly mild to moderate. The label also warns about pancreatitis, gallbladder disease, and kidney injury from dehydration. And it carries a boxed warning: tirzepatide caused thyroid tumors in rats, and whether it does in humans is unknown.
Long-term outcomes are the big open question. A trial of more than fifteen thousand adults with obesity is testing whether tirzepatide lowers deaths, heart attacks, strokes and heart failure events, with results expected in 2027. Another is testing it in teenagers with obesity.
Tirzepatide is FDA approved. Mounjaro was approved in 2022 for type 2 diabetes, after the SURPASS trials, and in 2026 also to lower the risk of heart attack, stroke and heart-related death in high-risk adults with diabetes. Zepbound is approved for weight management and for sleep apnea with obesity. Compounded copies are not FDA approved, and the FDA has warned sellers of so-called research versions.
Is Zepbound the same drug as Mounjaro? Yes, both are tirzepatide, approved for different uses. Does the weight stay off after stopping? In SURMOUNT-4, people switched to placebo regained much of what they had lost. And is compounded or research tirzepatide the approved drug? No. The FDA does not review compounded drugs before sale, and research vials have none of the manufacturing oversight.
The bottom line: tirzepatide is an approved medicine with large effects on weight and blood sugar, common digestive side effects, and outcome trials still under way. For every study and source, see the tirzepatide profile on PepsRadar dot com.
Biological role or research focus
Incretin-related glucose and appetite regulation.
Mounjaro, Zepbound, compounded preparations, and research products have distinct identities.
Role reference: MedlinePlus: Tirzepatide injection ↗
Names you may encounter
Mounjaro · Zepbound
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GIP / GLP-1 receptor agonist
- Main research area
- Diabetes, weight, and related indications
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Tirzepatide FDA approved?
- Yes. Mounjaro (NDA 215866, approved May 2022) for type 2 diabetes in adults, extended to children 10 and older in December 2025, and in August 2026 to lower the risk of heart attack, stroke and heart-related death in high-risk adults with type 2 diabetes. Source ↗
- Is Tirzepatide safe?
- Tirzepatide is a GIP/GLP-1 drug for weight and diabetes; stomach side effects are common, and the label warns of thyroid C-cell tumors in rats, pancreatitis, gallbladder disease and kidney injury. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Tirzepatide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Tirzepatide?
- Yes. Our records list 4 FDA actions naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| SURMOUNT-1 (2022) | Human randomized trial | 2,539 adults with obesity, or overweight and a weight-related complication, without diabetes. |
| T-REx: resistance exercise during tirzepatide treatment (2026) | Human randomized trial | 120 adults with overweight or obesity, all treated with tirzepatide, at the University of Western Australia. |
| SURPASS-2 direct comparison in type 2 diabetes (2021) | Human randomized trial | 1,879 patients with type 2 diabetes; mean baseline HbA1c 8.28%. |
| SURMOUNT-4 · continuation versus withdrawal (2024) | Human randomized withdrawal trial | 670 adults with overweight or obesity without diabetes who completed a 36-week open-label lead-in; 783 initially enrolled. |
Claim check
False Is 'research' retatrutide or semaglutide the same as the real drug?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2022
SURMOUNT-1
Tirzepatide Once Weekly for the Treatment of Obesity.
- Population / model
- 2,539 adults with obesity, or overweight and a weight-related complication, without diabetes.
- Study design
- Seventy-two-week blinded placebo-controlled study with gradual escalation.
- Main finding
- Mean weight reductions were 15.0%, 19.5%, and 20.9% across active groups versus 3.1% with placebo. Gastrointestinal effects were common.
- Limits & context
- This trial cannot be compared directly with STEP 1 as if participants were randomized between the two drugs. Outcomes depend on population, duration, regimen, and handling of discontinuation.
Source: Tirzepatide Once Weekly for the Treatment of Obesity. ↗
Human randomized trial · 2026
T-REx: resistance exercise during tirzepatide treatment
Does supervised strength training reduce the lean mass and strength lost while losing weight on tirzepatide?
- Population / model
- 120 adults with overweight or obesity, all treated with tirzepatide, at the University of Western Australia.
- Study design
- Two-arm randomized trial: tirzepatide alone (usual activities) versus tirzepatide plus supervised resistance exercise three times a week, for 40 weeks. Primary outcomes: change in total fat mass and total lean soft tissue mass.
- Main finding
- Weight loss was similar (-22.6 kg alone, -22.3 kg with exercise), as was fat loss (-17.2 vs -18.0 kg). Lean soft tissue loss was smaller with exercise (-3.6 vs -4.7 kg). Strength fell on tirzepatide alone (bench press -4.1 kg, lat pulldown -4.4 kg, knee extension -4.4 kg) but rose with exercise (+4.7, +8.6 and +5.9 kg). Exercise sessions had 91% adherence, and most participants tolerated the full dose increase.
- How to read it
- Strength training did not change how much weight people lost, but it reduced lean mass loss and turned a measured loss of strength into a gain.
- Limits & context
- A 40-week trial in 120 people; it cannot show effects on falls, fractures or long-term function, and participants were not blinded to exercise. Several authors report speaker fees or advisory roles with Eli Lilly. Results apply to the approved drug used under medical supervision.
Source: T-REx · Nature Medicine · 2026 ↗
Human randomized trial · 2021
SURPASS-2 direct comparison in type 2 diabetes
How did the studied tirzepatide regimens compare with semaglutide in this diabetes trial?
- Population / model
- 1,879 patients with type 2 diabetes; mean baseline HbA1c 8.28%.
- Study design
- Open-label randomized phase 3 trial lasting 40 weeks. Three tirzepatide groups were compared with semaglutide at its diabetes dose.
- Main finding
- Mean HbA1c fell by 2.01–2.30 percentage points in the tirzepatide groups and 1.86 with semaglutide. Weight reductions were greater with tirzepatide; between-group differences ranged from 1.9 to 5.5 kg. Gastrointestinal adverse effects were common.
- How to read it
- This is a direct comparison, but only for its actual regimens, population, and outcomes. HbA1c percentage points and percentage weight change are different measures.
- Limits & context
- Open-label design; the semaglutide comparator was its diabetes dose, not the higher weight-management dose. It is not a universal ranking across all products or doses. Funded by Eli Lilly.
Human randomized withdrawal trial · 2024
SURMOUNT-4 · continuation versus withdrawal
Was initial weight reduction maintained after switching to placebo?
- Population / model
- 670 adults with overweight or obesity without diabetes who completed a 36-week open-label lead-in; 783 initially enrolled.
- Study design
- Randomized double-blind comparison of continued tirzepatide with placebo for another 52 weeks, alongside diet and activity.
- Main finding
- After a mean 20.9% reduction during lead-in, weight changed by −5.5% with continued treatment versus +14.0% with placebo from week 36 to week 88. At least 80% of the lead-in loss was maintained by 89.5% versus 16.6%.
- How to read it
- The randomized-period change and the total change from enrollment use different baselines. They should not be conflated.
- Limits & context
- Only lead-in completers were randomized. Gastrointestinal events were more common with continued treatment. This does not determine an individual stopping plan or prove that every patient will regain the same amount.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
79 registered studies name Tirzepatide as an intervention among the 100 most recently updated of 320 search results; 52 are recruiting or under way, 17 have not started recruiting yet and 10 completed. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 79 listed studies.
Search additional PubMed records ↗Risks & interactions
Tirzepatide is a GIP/GLP-1 drug for weight and diabetes; stomach side effects are common, and the label warns of thyroid C-cell tumors in rats, pancreatitis, gallbladder disease and kidney injury.
Caused thyroid C-cell tumors in rats; it is unknown whether it does in humans. Do not use with a personal or family history of medullary thyroid carcinoma or with MEN 2.
Safety is established by FDA labeling and large trials. This entry summarizes the Zepbound label; the diabetes brand Mounjaro has its own label. Whether the rat thyroid tumors matter for humans is unknown.
Take extra care with: Blood thinners or bleeding problemsDiabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeedingKidney problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious allergy to tirzepatide or any ingredient
- Severe gastroparesis (very slow stomach emptying): not recommended
- Pregnancy: may cause fetal harm, and the label says to stop when pregnancy is recognized
Interactions
- Insulin or sulfonylureas: higher risk of low blood sugar
- Oral medicines, especially narrow-margin ones such as warfarin: slowed stomach emptying may change absorption
- Birth control pills: may be less effective; the label advises a non-oral or added barrier method around starting and dose increases
Serious risks
- Severe stomach and bowel side effects
- Kidney injury from dehydration
- Gallbladder disease
- Acute pancreatitis
- Serious allergic reactions, including anaphylaxis and angioedema
- Low blood sugar with insulin or sulfonylureas, and inhaling stomach contents during anesthesia
Common side effects
- nausea
- diarrhea
- vomiting
- constipation
- abdominal pain
- indigestion
- injection-site reactions
- hair loss
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Zepbound (tirzepatide) prescribing information ↗
Key precautions
Gastrointestinal reactions, dehydration, pancreatic and gallbladder concerns, and thyroid-tumor warnings matter. Pregnancy planning, oral contraception, and other diabetes medicines require specific clinical review.
Source: MedlinePlus: Tirzepatide injection ↗
Regulatory status
- U.S. FDA approval
- Approved
Mounjaro (NDA 215866, approved May 2022) for type 2 diabetes in adults, extended to children 10 and older in December 2025, and in August 2026 to lower the risk of heart attack, stroke and heart-related death in high-risk adults with type 2 diabetes; Zepbound (NDA 217806, approved November 2023) for chronic weight management and obstructive sleep apnea with obesity. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not prohibited. Tirzepatide markers are on WADA's 2026 Monitoring Program (tracked for misuse patterns, not banned). source
FDA actions
- FDA proposed excluding tirzepatide (with semaglutide and liraglutide) from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk. (2026-04-30) source
- FDA statement announcing intent to restrict GLP-1 APIs used in mass-marketed non-approved compounded drugs and to act on misleading marketing. (2026-02-06) source
- FDA page on risks of unapproved and compounded GLP-1 drugs, including fraudulent compounded tirzepatide and "research use only" sellers (updated October 1, 2026). (2026-10-01) source
- FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source
Other notes
- Tirzepatide is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source
- WADA 2026 Monitoring Program includes markers of tirzepatide (in and out of competition). source
- Canada, November 6, 2026: Health Canada warned consumers not to buy or inject unauthorized peptides sold online after lab tests of vials seized from a Chinese supplier found bacteria, including Acinetobacter seifertii, Acinetobacter nosocomialis and Cutibacterium acnes. It seized over 11,400 vials from the supplier and two Canadian online retailers, whose websites are no longer active. Unauthorized products sold as tirzepatide were among the example products listed. Authorized drugs for sale in Canada carry an 8-digit Drug Identification Number (DIN) on the label. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The medication reference covers selected diabetes and weight-management populations and obstructive sleep apnea in adults with obesity. The exact product label defines eligibility and use.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
Mechanism & research rationale
It activates GIP and GLP-1 receptor pathways. Effects on glucose regulation, stomach emptying, and appetite are evaluated through indication-specific clinical trials.
Molecular structure
Questions worth asking
- Which exact product is being discussed?
- Is a podcast describing a study, an approved indication, or a personal experience?
- Mounjaro, Zepbound, compounded preparations, and research products have distinct identities.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Are Mounjaro and Zepbound the same indication?
No. They contain the same molecule but have distinct product-label contexts.
Does SURMOUNT-1 validate every seller’s tirzepatide?
No. A study of a controlled pharmaceutical preparation cannot establish another product’s identity, potency, or clinical safety.
Source: Tirzepatide Once Weekly for the Treatment of Obesity. ↗
What does the SURPASS-2 direct comparison in type 2 diabetes study show, and what does it not?
This is a direct comparison, but only for its actual regimens, population, and outcomes. HbA1c percentage points and percentage weight change are different measures. Open-label design; the semaglutide comparator was its diabetes dose, not the higher weight-management dose. It is not a universal ranking across all products or doses. Funded by Eli Lilly.
References & editorial record
- FDA · Unapproved GLP-1 products ↗
- MedlinePlus: Tirzepatide injection ↗
- Tirzepatide Once Weekly for the Treatment of Obesity. ↗
- T-REx · Nature Medicine · 2026 ↗
- Frias et al. · NEJM · SURPASS-2 · 2021 ↗
- Aronne et al. · JAMA · SURMOUNT-4 · 2024 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Semaglutide, tirzepatide, retatrutide: why trial context changes the comparison
Understand direct comparisons, diabetes versus obesity populations, and the difference between glucose, weight, and cardiovascular outcomes.
Read the guide →RESEARCH FIELD GUIDE
Semaglutide not working? Why some people lose less, and what the trials show
Most people on semaglutide lose meaningful weight, but not everyone does. How many respond in the trials, why people with type 2 diabetes tend to lose less, what a new gene study found, and what the evidence says about switching or stopping.
Read the guide →RESEARCH FIELD GUIDE
Semaglutide and NAION: the FDA’s new vision warning, in numbers
On November 9, 2026 the FDA required every GLP-1 medicine, including semaglutide (Ozempic, Wegovy, Rybelsus), to carry a warning about NAION, a rare optic-nerve condition. How rare it is, where the concern came from, how strong the evidence is, and which symptoms need a same-day call.
Read the guide →RESEARCH FIELD GUIDE
What happens when you stop semaglutide? What the trials show
In the trials, most people who stopped semaglutide (Ozempic, Wegovy) regained much of the weight within a year, and gains in blood pressure and blood sugar faded too. The numbers from STEP 1, STEP 4 and tirzepatide’s SURMOUNT-4, and what the evidence says may help.
Read the guide →RESEARCH FIELD GUIDE
Semaglutide vs tirzepatide: what the head-to-head trials show
Only two randomized trials have compared semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) directly. Tirzepatide led to more weight loss in both. Here are the numbers, the side effects, the different heart-outcome evidence for each, and the caveats.
Read the guide →RESEARCH FIELD GUIDE
Orforglipron (Foundayo): the GLP-1 pill, explained
Orforglipron (Foundayo) is a once-daily GLP-1 pill the FDA approved for weight loss in April 2026. What it is, why it isn’t a peptide, what the ATTAIN and ACHIEVE trials found, how it compares with the injections, and its side effects and warnings.
Read the guide →RESEARCH FIELD GUIDE
When will retatrutide be approved? Where Lilly’s FDA application stands
Retatrutide is not approved anywhere yet. Eli Lilly says it plans to submit it to the FDA in the first quarter of 2027. How long FDA review usually takes, what the application will rest on, and why nothing sold as retatrutide today is the real thing.
Read the guide →RESEARCH FIELD GUIDE
GLP-1 side effects compared: semaglutide, tirzepatide, retatrutide and orforglipron
Stomach and gut problems topped the side-effect list in the main obesity trials of all four drugs. What STEP 1, SURMOUNT-1, TRIUMPH-1 and ATTAIN-1 reported, why the numbers don't line up neatly, and the warnings the class shares.
Read the guide →RESEARCH FIELD GUIDE
GLP-1s and muscle: how much lean mass do you lose, and does lifting help?
Body scans from semaglutide and tirzepatide trials show that part of the weight lost is lean mass. Here is how much, why lean mass is not the same as muscle, what a 2026 trial found when people lifted weights, and what is still unknown.
Read the guide →RESEARCH FIELD GUIDE
GLP-1s and keto: a real-food playbook for losing fat, not muscle
A GLP-1 medicine turns down your appetite. What you eat with that smaller appetite decides how much of the weight you lose is fat and how much is muscle. Lived experience and the published research on cutting carbs, ketones, electrolytes, kidney stones, muscle, fasting, real food and sleep, including where the evidence is thin.
Read the guide →









